AgomAb IPO Debuts Below Price, Raises $200M
Clinical-stage biopharma firm AgomAb Therapeutics closed its first trading day 8.4% below its IPO price, raising $200 million. The Belgian company focuses on treatments for Crohn's disease and rare lung conditions.


